Bionor is a biopharmaceutical company with first mover potential to advance a possible functional HIV cure

Latest news

Hide mandatory notifications of trade

The peer-reviewed and highly recognized journal 'The Lancet HIV' has published the results of the REDUC Part B trial

Financial .2016

(Oslo, Norway, 9 July 2016) Bionor Pharma ASA (Bionor) (OSE:BIONOR) announced today that the positive results from the clinical trial REDUC Part B has been published for the first time in the peer-reviewed and highly recognized journal The Lancet HIV.

Bionor provides update on funding

Financial .2016

(Oslo, Norway, 30 June 2016) Referring to stock exchange announcement as of 20 June 2016, the Board of Directors of Bionor Pharma ASA announced today, that the contemplated private placement of up to about NOK 70 million will be postponed until the ongoing pre-sounding phase has been concluded and alternative strategic solutions have also been sufficiently investigated.

Bionor releases updated investor presentation

Financial .2016

(Oslo, Norway, 21 June 2016) Bionor Pharma ASA (OSE:BIONOR) announced today, that the company has updated its investor presentation.

The peer-reviewed and highly recognized journal 'The Lancet HIV' has published the results of the REDUC Part B trial

Financial .2016

(Oslo, Norway, 9 July 2016) Bionor Pharma ASA (Bionor) (OSE:BIONOR) announced today that the positive results from the clinical trial REDUC Part B has been published for the first time in the peer-reviewed and highly recognized journal The Lancet HIV.

Bionor provides update on funding

Financial .2016

(Oslo, Norway, 30 June 2016) Referring to stock exchange announcement as of 20 June 2016, the Board of Directors of Bionor Pharma ASA announced today, that the contemplated private placement of up to about NOK 70 million will be postponed until the ongoing pre-sounding phase has been concluded and alternative strategic solutions have also been sufficiently investigated.

Bionor releases updated investor presentation

Financial .2016

(Oslo, Norway, 21 June 2016) Bionor Pharma ASA (OSE:BIONOR) announced today, that the company has updated its investor presentation.

Go to news section

Featured content